Latest & greatest articles for anticoagulation

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on anticoagulation or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on anticoagulation and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for anticoagulation

421. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. (Abstract)

A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. Antithrombotic drugs are used after coronary-artery stenting to prevent stent thrombosis. We compared the efficacy and safety of three antithrombotic-drug regimens - aspirin alone, aspirin and warfarin, and aspirin and ticlopidine - after coronary stenting.Of 1965 patients who underwent coronary stenting at 50 centers, 1653 (84.1 percent) met

1998 NEJM Controlled trial quality: uncertain

422. Anticoagulant options in heparin-induced thrombocytopenia

Anticoagulant options in heparin-induced thrombocytopenia Anticoagulant options in heparin-induced thrombocytopenia Anticoagulant options in heparin-induced thrombocytopenia University HealthSystem Consortium Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation University HealthSystem Consortium. Anticoagulant options in heparin-induced thrombocytopenia. Oak Brook (...) , Illinois: University Healthsystem Consortium 1998: 64 Authors' objectives Provides an in-depth analysis of four alternative therapies for patients who have HIT: danaparoid sodium, lepirudin, argatroban, and ancrod. Recommendations for use also are included. Project page URL Indexing Status Subject indexing assigned by CRD MeSH Anticoagulants; Heparin; Thrombocytopenia /drug therapy Language Published English Country of organisation United States Address for correspondence University HealthSystem

1998 Health Technology Assessment (HTA) Database.

423. An overview of the effect of computer-assisted management of anticoagulant therapy on the quality of anticoagulation

An overview of the effect of computer-assisted management of anticoagulant therapy on the quality of anticoagulation An overview of the effect of computer-assisted management of anticoagulant therapy on the quality of anticoagulation An overview of the effect of computer-assisted management of anticoagulant therapy on the quality of anticoagulation Chatellier G, Colombet I, Degoulet P Authors' objectives To assess the effectiveness of computer-assisted prescription systems on the quality (...) of anticoagulation. Searching The authors searched MEDLINE from 1966 onwards using MeSH keywords: 'computer systems', 'decision- making', computer-assisted'; 'drug therapy', 'computer-assisted'; 'evaluation studies'; and 'randomized controlled trials'. Keywords were searched in the title, the summary, and the subject headings of MEDLINE. The references of selected full papers were searched for additional relevant trials. Study selection Study designs of evaluations included in the review Randomised controlled

1998 DARE.

424. Cost-effectiveness of anticoagulation in nonrheumatic atrial fibrillation in the primary prevention of ischemic stroke

Cost-effectiveness of anticoagulation in nonrheumatic atrial fibrillation in the primary prevention of ischemic stroke Cost-effectiveness of anticoagulation in nonrheumatic atrial fibrillation in the primary prevention of ischemic stroke Cost-effectiveness of anticoagulation in nonrheumatic atrial fibrillation in the primary prevention of ischemic stroke Lightowlers S, McGuire A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED (...) . Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Anticoagulation in nonrheumatic atrial fibrillation (NRAF) in the primary prevention of ischemic stroke. Type of intervention Primary prevention. Economic study type Cost-effectiveness analysis. Study population Patients with NRAF with no contraindication to anticoagulation. Setting Hospital

1998 NHS Economic Evaluation Database.

425. A cost-effectiveness analysis of aspirin versus oral anticoagulants after acute myocardial infarction in Italy: equivalence of costs as a possible case for oral anticoagulants

A cost-effectiveness analysis of aspirin versus oral anticoagulants after acute myocardial infarction in Italy: equivalence of costs as a possible case for oral anticoagulants A cost-effectiveness analysis of aspirin versus oral anticoagulants after acute myocardial infarction in Italy: equivalence of costs as a possible case for oral anticoagulants A cost-effectiveness analysis of aspirin versus oral anticoagulants after acute myocardial infarction in Italy: equivalence of costs as a possible (...) case for oral anticoagulants Gianetti J, Gensini G, De Caterina R Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Aspirin (antiplatelet) and warfarin (anticoagulant) for the prevention of coronary artery disease after acute

1998 NHS Economic Evaluation Database.

426. Primary care anticoagulant clinic management using computerized decision support and near patient international normalized ratio (INR) testing: routine data from a practice nurse-led clinic

Primary care anticoagulant clinic management using computerized decision support and near patient international normalized ratio (INR) testing: routine data from a practice nurse-led clinic Primary care anticoagulant clinic management using computerized decision support and near patient international normalized ratio (INR) testing: routine data from a practice nurse-led clinic Primary care anticoagulant clinic management using computerized decision support and near patient international (...) normalized ratio (INR) testing: routine data from a practice nurse-led clinic Fitzmaurice D A, Hobbs F D, Murray E T Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Primary care anticoagulant clinic management. Type of intervention

1998 NHS Economic Evaluation Database.

427. Evaluation of excessive anticoagulation in a group model health maintenance organization

Evaluation of excessive anticoagulation in a group model health maintenance organization Evaluation of excessive anticoagulation in a group model health maintenance organization Evaluation of excessive anticoagulation in a group model health maintenance organization Lousberg T R, Witt D M, Beall D G, Carter B L, Malone D C Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods (...) , the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Using phytonadione and/or fresh frozen plasma (FFP) versus the conservative management option in the management of patients with excessive anticoagulation. The conservative management was defined as temporary discontinuation of warfarin therapy until the international normalized ratio (INR) falls to within therapeutic range. Type of intervention Secondary

1998 NHS Economic Evaluation Database.

428. Evaluation of a decision support system for initiation and control of oral anticoagulation in a randomised trial. Full Text available with Trip Pro

Evaluation of a decision support system for initiation and control of oral anticoagulation in a randomised trial. To determine whether a computerised decision support system for initiation and control of oral anticoagulant treatment improves quality of anticoagulant control achieved by trainee doctors.Randomised controlled trial.District general hospital in North London.148 inpatients requiring start of warfarin treatment.Management by trainee doctors (to achieve therapeutic range (...) of > or = 2 was not significantly different in the two groups (3 days). Median time to achieve a stable dose was significantly lower in intervention group than in controls (7 days v 9 days, P = 0.01) without excessive overtreatment or undertreatment with anticoagulant. Patients in intervention group spent greater proportion of time in therapeutic range, both as inpatients (59% v 52%) and outpatients (64% v 51%).The computerised decision support system was safe and effective and improved the quality

1997 BMJ Controlled trial quality: uncertain

429. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. The Post Coronary Artery Bypass Graft Trial Investigators. Full Text available with Trip Pro

The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. The Post Coronary Artery Bypass Graft Trial Investigators. Obstructive changes often occur in aortocoronary saphenous-vein bypass grafts because of atherosclerosis and thrombosis. We studied whether aggressive lowering of low-density lipoprotein (LDL) cholesterol levels or low-dose anticoagulation would delay

1997 NEJM Controlled trial quality: uncertain

430. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group. (Abstract)

The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group. A consensus has not been reached about the optimal duration of oral anticoagulant therapy after a second episode of venous thromboembolism.In a multicenter trial, we compared six months of oral anticoagulant therapy with anticoagulant therapy continued indefinitely in patients who had had a second episode of venous thromboembolism. Of 227 patients (...) enrolled, 111 were randomly assigned to six months of anticoagulation and 116 were assigned to receive anticoagulant therapy indefinitely; for both groups, the target international normalized ratio was 2.0 to 2.85. The initial episodes of deep-vein thrombosis (n = 193) and pulmonary embolism (n = 34), as well as recurrent episodes, were all objectively confirmed.After four years of follow-up, there were 26 recurrences of venous thromboembolism that fulfilled the diagnostic criteria, 23 in the group

1997 NEJM Controlled trial quality: uncertain

431. Anticoagulation in spinal surgery: a critical review of the literature

Anticoagulation in spinal surgery: a critical review of the literature Anticoagulation in spinal surgery: a critical review of the literature Anticoagulation in spinal surgery: a critical review of the literature Catre M G Authors' objectives To critically appraise the existing literature regarding thromboprophylaxis in elective spinal surgery. Searching MEDLINE was searched from 1965 to 1995 using the keywords 'anticoagulation', 'DVT' and 'spine', alone and in different combinations (...) from the findings of these studies because of the lack of good scientific evidence. Research: The author states that there is a need for a well-designed randomised, double-blind, placebo-controlled study of anticoagulation in spinal surgery. Bibliographic details Catre M G. Anticoagulation in spinal surgery: a critical review of the literature. Canadian Journal of Surgery 1997; 40(6): 413-419 Indexing Status Subject indexing assigned by NLM MeSH Adolescent; Adult; Anticoagulants /therapeutic use

1997 DARE.

432. Costs and effectiveness of a nurse specialist anticoagulant service

Costs and effectiveness of a nurse specialist anticoagulant service Costs and effectiveness of a nurse specialist anticoagulant service Costs and effectiveness of a nurse specialist anticoagulant service Taylor F C, Gray A, Cohen H, Gaminara L, Ramsay M, Miller D Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical (...) assessment on the reliability of the study and the conclusions drawn. Health technology A nurse specialist service in anticoagulation treatment. Type of intervention Secondary prevention. Economic study type Cost-effectiveness analysis. Study population Patients referred to anticoagulant clinics for anticoagulation treatment. Setting Institution. The economic study was performed in the UK. Dates to which data relate The authors did not clearly establish the dates to which effectiveness data referred

1997 NHS Economic Evaluation Database.

433. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. (Abstract)

A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. The clinical benefit of coronary-artery stenting performed in conjunction with coronary angioplasty is limited by the risk of thrombotic occlusion of the stent as well as hemorrhagic and vascular complications of intensive anticoagulation. We compared antiplatelet therapy with conventional anticoagulant therapy with respect to clinical outcomes 30 days after coronary-artery (...) stenting.After successful placement of Palmaz-Schatz coronary-artery stents, 257 patients were randomly assigned to receive antiplatelet therapy (ticlopidine plus aspirin) and 260 to receive anticoagulant therapy (intravenous heparin, phenprocoumon, and aspirin). The primary cardiac end point was a composite measure reflecting death from cardiac causes or the occurrence of myocardial infarction, aortocoronary bypass surgery, or repeat angioplasty. The primary noncardiac end point comprised death from

1996 NEJM Controlled trial quality: predicted high

434. A comparison of aspirin and anticoagulation following thrombolysis for myocardial infarction (the AFTER study): a multicentre unblinded randomised clinical trial. Full Text available with Trip Pro

A comparison of aspirin and anticoagulation following thrombolysis for myocardial infarction (the AFTER study): a multicentre unblinded randomised clinical trial. To compare aspirin with anticoagulation with regard to risk of cardiac death and reinfarction in patients who received anistreplase thrombolysis for myocardial infarction.A multicentre unblinded randomised clinical trial.38 hospitals in six countries.1036 patients who had been treated with anistreplase for myocardial infarction were (...) randomly assigned to either aspirin (150 mg daily) or anticoagulation (intravenous heparin followed by warfarin or other oral anticoagulant). The trial was stopped earlier than originally intended because of the slowing rate of recruitment.Cardiac death or recurrent myocardial infarction at 30 days.After 30 days cardiac death or reinfarction, occurred in 11.0% (57/517) of the patients treated with anticoagulation and 11.2% (58/519) of the patients treated with aspirin (odds ratio 1.02, 95% confidence

1996 BMJ Controlled trial quality: predicted high

435. Bleeding risk of combined oral anticoagulant and antiplatelet therapy in cardiovascular disease

Bleeding risk of combined oral anticoagulant and antiplatelet therapy in cardiovascular disease Bleeding risk of combined oral anticoagulant and antiplatelet therapy in cardiovascular disease Bleeding risk of combined oral anticoagulant and antiplatelet therapy in cardiovascular disease Verheugt F W Authors' objectives To assess the safety of combining oral anticoagulant and antiplatelet therapy. Searching EMBASE was searched from 1960 to 1994. [A: The search strategy was not defined. Only (...) papers written in the English language were included]. Study selection Study designs of evaluations included in the review Clinical trials, of which most were randomised, were included. Specific interventions included in the review Combinations of anticoagulants and antiplatelet therapy, compared with either intervention alone or with placebo, namely: acenocoumarin (alone and with aspirin), warfarin (alone or with placebo, aspirin or dipyridamole), aspirin (alone and with warfarin), double placebo

1996 DARE.

436. Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: systematic overview of randomised trials

Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: systematic overview of randomised trials Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: systematic overview of randomised trials Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: systematic overview of randomised trials Collins R, MacMahon S, Flather M, Baigent C, Remvig L, Mortensen S, Appleby P, Godwin J, Yusuf S, Peto R Authors' objectives (...) To determine the effect of early anticoagulation on the mortality and other major clinical events in patients with suspected acute myocardial infarction (MI), and to assess the effect of adding heparin to aspirin. Searching A formal computer-aided literature search was undertaken. Additional materials was located by examining reference lists, and by contacting other investigators and pharmaceutical companies. Study selection Study designs of evaluations included in the review Randomised controlled trials

1996 DARE.

437. Cost-effectiveness of prophylactic anticoagulation prolonged after hospital discharge following general surgery

Cost-effectiveness of prophylactic anticoagulation prolonged after hospital discharge following general surgery Cost-effectiveness of prophylactic anticoagulation prolonged after hospital discharge following general surgery Cost-effectiveness of prophylactic anticoagulation prolonged after hospital discharge following general surgery Sarasin F P, Bounameaux H Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract (...) contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Prolonged self-administered prophylactic low-dose low-molecular-weight heparin (LMWH) during 4 weeks after hospital discharge versus anticoagulant therapy with heparin started immediately after the first clinically overt venous thromboembolism (VTE). Type of intervention Primary prevention. Economic study type Cost

1996 NHS Economic Evaluation Database.

438. Antithrombotic strategy after total hip replacement: a cost-effectiveness analysis comparing prolonged oral anticoagulants with screening for deep vein thrombosis

Antithrombotic strategy after total hip replacement: a cost-effectiveness analysis comparing prolonged oral anticoagulants with screening for deep vein thrombosis Antithrombotic strategy after total hip replacement: a cost-effectiveness analysis comparing prolonged oral anticoagulants with screening for deep vein thrombosis Antithrombotic strategy after total hip replacement: a cost-effectiveness analysis comparing prolonged oral anticoagulants with screening for deep vein thrombosis Sarasin F (...) P, Bounameaux H Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Prolonged oral anticoagulant therapy was compared with screening in the prevention of deep vein thrombosis (DVT) after total hip replacement. Type of intervention

1996 NHS Economic Evaluation Database.

439. Atrial fibrillation: restoration and maintenance of sinus rhythm and indications for anticoagulation therapy

Atrial fibrillation: restoration and maintenance of sinus rhythm and indications for anticoagulation therapy Atrial fibrillation: restoration and maintenance of sinus rhythm and indications for anticoagulation therapy Atrial fibrillation: restoration and maintenance of sinus rhythm and indications for anticoagulation therapy Golzari H, Cebul R D, Bahler R C Authors' objectives To review the efficacy and safety of electrical and pharmacological conversion of atrial fibrillation, strategies (...) examined in this context, along with surgical corridor and maze procedures. In addition, antithrombotic therapy is examined, and the effectiveness of warfarin, aspirin and anticoagulants is assessed. Participants included in the review Patients with atrial fibrillation. A small number of studies included patients with fibrillation after cardiac surgery. Outcomes assessed in the review The main outcome was restoration of sinus rhythm. Reduction in incidence of ischaemic stroke and emboli is also

1996 DARE.

440. Costs and effects of long-term oral anticoagulant treatment after myocardial infarction. (Abstract)

Costs and effects of long-term oral anticoagulant treatment after myocardial infarction. To investigate the costs and effects of long-term oral anticoagulant treatment after myocardial infarction.Cost-effectiveness analysis, based on a randomized, double-blind, placebo-controlled trial.Sixty Dutch hospitals.A total of 3404 hospital survivors of acute myocardial infarction randomized within a median period of 4 days after discharge to either oral anticoagulant treatment or placebo. The mean (...) follow-up was 37 months.Oral anticoagulant treatment aimed at a target international normalized ratio of 2.8 to 4.8.Costs of hospital stay during readmissions, costs related to major cardiologic interventions, and costs of oral anticoagulant treatment.The costs of oral anticoagulant treatment were estimated at 394 Dutch guilders (Dfl) per patient-year (Dfl 1 = US $0.58). Placebo patients stayed 18,830 days in the hospital compared with 15,083 days for anticoagulation patients. Average costs per

1995 JAMA Controlled trial quality: predicted high